We are glad to report that the inception of the Journal of Pharmacovigilance has been greeted with enthusiasm, as reflected in a constant flux of submissions. We believe that open-access if the way of the future when it comes to scientific reports in general and Pharmacovigilance reports in particular. In our opinion, medication safety is a public health issue and as such what better venue to address it than an open-access publication? Of course our impact greatly depends on you, our readership. Please keep your submissions coming. While we cannot guarantee publication, as rigorous peer review always results in a fair number of rejections, we promise that no paper will be rejected without explanation. It is part of our mission to have our peer reviewers and editors help you improve the quality of your report independent of your decision to resubmit here or elsewhere.
Drug induced hypersensitivity is an important clinical issue. Any patient can be sensitive to any drug and other than an informative discussion about the risk for a possible allergic reaction the assessment of hypersensitivity is usually completed by a “wait and see approach”. Our poor ability to test prospectively for hypersensitivity results in not only in significant treatment delays but increases in costs related to both a decrease in efficacy (as an ideal efficacious drug would work the first time around, i.e. each drug failure amounts to a loss of efficacy) and in increase in toxicity. Teixeira and colleagues offer an elegant solution to this conundrum reporting that the assessment of CD69 and CD25 activation markers appears to be an useful prospective marker of drug allergy diagnosis in immediate and in delayed hypersensitivity.